VOLITION AMERICA - Key Persons
Job Titles:
- Chief Executive Officer
- Group Chief Executive Officer
- Member of the Nominations and Governance Team
- President
Cameron is the President and Group Chief Executive Officer of Volition and was one of the founders of the company in 2010. He is an experienced entrepreneurial executive, with expertise in a wide range of fields, including several biotechnology companies and has led Volition through the research and development of Volition's proprietary Nucleosomics™ to the commercialization of its first test, the Nu.Q™ Vet Cancer Screening Test. Cameron has extensive experience in the management, structuring, and financing of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, Chairman, and Non-Executive Director of public and private enterprises.
Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.
Job Titles:
- Independent Director
- Member of the Audit Committee
- Member of the Nominations and Governance Team
- Audit
Alan Colman obtained a BA degree in Biochemistry in Oxford (1971) and a PhD under John Gurdon, a pioneer of the field of nuclear transfer, at the Laboratory of Molecular Biology in Cambridge, UK (1974). After a series of academic appointments in Oxford and Warwick Universities, he became Professor of Biochemistry in the University of Birmingham, UK from 1987-1992. The focus then of his academic career was the area of eucaryotic protein secretion, with a particular emphasis on the use of frog oocytes and eggs as in vivo test tubes.
From 1987 until March 2002, he was research director of the company PPL Therapeutics in Edinburgh, UK. This company specialized in the production of transgenic livestock that produced human therapeutic proteins in their milk. PPL attracted considerable media attention because of their use of somatic cell nuclear transfer in a collaboration with the neighboring Roslin Institute. This work led to Dolly, the world's first sheep cloned from an adult somatic cell (1996).
From 2002-2007, he was CSO and then CEO for the Singaporean human embryonic stem cell company, ES Cell International. Following this, he served as Executive Director of the Singapore Stem Cell Consortium and a Principal Investigator at the Singapore A*STAR Institute of Medical Biology (2006-2013) whilst concurrently Professor of Regenerative Medicine at King's College, London, UK (2008-2009). His main research interest during these appointments was the development of human disease models using induced pluripotent stem cells.
In addition to his roles with Volition (2011- present), Dr. Alan Colman acts as senior scientific advisor to Genea Biocells in San Diego, USA, and is a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology (2014- present).
Job Titles:
- Professor for Protein Analytics at the Biomedical Center
Dr. Axel Imhof is a professor for protein analytics at the Biomedical Center of the Ludwig-Maximilians University of Munich (LMU) and the director of the Proteomics Core Facility of LMUs Biomedical Center. His lab is among the world leading groups for the characterization of chromatin bound proteins and the characterization of histone modifications using mass spectrometry. He is also the Cofounder of EpiQMAx, a company dedicated to the quantitative analysis of histone modifications in clinical samples. Dr. Imhof has been a member of several national and international clusters of excellence and acts as academic editor for several scientific journals. He is a Co-speaker of the Core Facilities group of the German Society of Mass Spectrometry and an elected member of the European Molecular Biology Organization (EMBO).
Job Titles:
- Independent Director
- Member of the Audit Committee
- Member of the Nominations and Governance Team
- Audit
- Member of Nominations and Governance Committee
Dr. Futcher holds a B.Sc. in Physics and a Ph.D. in Physics from the University of London and has extensive experience in engineering and management in high technology companies. Since 1997, Dr. Futcher has held non-executive directorships at a variety of private companies. He co-founded Azima, Inc. in 2003, a company that provides advanced machine diagnosis to large industrial facilities and, from 2003 to 2008, served as its Vice President of Engineering. Prior to that, from 1997 to 2003, Dr. Futcher served as Vice President of Technology at interWAVE Communications International Ltd., a company providing GSM and CDMA cellular infrastructure equipment, and from 1997 to 1999 he also served as interWAVE's Vice President of Engineering. From 1994 to 1997, Dr. Futcher was Director of Engineering at Tellabs, Inc.
Gaetan is the Chief Operating Officer and has been a valued member of the Volition team since 2014 serving firstly as Chief Operating Officer of Belgian Volition and latterly as Chief Executive Officer of Belgian Volition. With over 15 years' project management, manufacturing and operational experience, Gaetan is ideally placed to oversee and expand Volition's global operations including the newly opened Innovation Hub in San Diego, the manufacturing facility "Silver One" and Research & Development Facility in Belgium, as well as expanding the Veterinary subsidiary in Texas, USA
Job Titles:
- Director of Experimental Pathology at Memorial Sloan Kettering Cancer Center
Dr. Jorge Reis-Filho is the Director of Experimental Pathology at Memorial Sloan Kettering Cancer Center in New York. His research focuses on massively parallel sequencing analysis of rare types of breast cancers for the development of a predictive molecular classification of the disease and on the characterization of intratumor genetic heterogeneity based on an integration of pathology methods, bioinformatics, single cell and circulating cell-free DNA sequencing.
Job Titles:
- Chief Technology Officer
- Managing Director of OncoLytika Ltd
Mark is the Chief Technology Officer and one of the founding scientists of Volition. He is an enthusiastic and passionate biotechnology entrepreneur with over 25 years' experience in the sector. He is focused not only on identifying new and innovative technology platforms, but also on ensuring they are fit for purpose now and in the future, all of which will aid the deployment of Volition's proprietary Nu.Q™ platform
Mark is also the Managing Director of OncoLytika Ltd. a technical consultancy company working with international private and public limited companies operating in the diagnostics and therapeutic sectors as well as academia.
Mark received a PhD in Polymer Chemistry for biomedical applications and an MBA (entrepreneurship) from the University of Dundee in 2008.
Dr. Mark Eccleston, one of Volition's founding scientists will now serve as our new Chief Technology Officer. Dr. Eccleston has over 20 years' experience in the biotechnology sector and holds a PhD in Polymer Chemistry for biomedical applications. In this new role, he will identify and review new and innovative infrastructures which will aid in the deployment of Volition's proprietary Nu.Q™ platform.
Job Titles:
- Chairman
- Executive Chairman
- Member of the Nominations and Governance Team
Martin has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. From 1979 to 1984, Martin was the Founder, President and CEO for Logica Inc., a company providing bespoke software to all…
Dr. Martin Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States.
From 1979 to 1984, Dr. Faulkes was the Founder, President and CEO for Logica Inc., a company providing bespoke software to all industries but mainly banks and communications companies. Dr. Faulkes was responsible for all aspects of the business; namely sales, finance, recruitment,staff management and project control. He then became Managing Director of System Programming Ltd., a company that provides computer programming for systems in business like airlines, utility companies, banks, and insurance, from 1985 to 1987, where he was responsible for all aspects of the business. Dr. Faulkes founded Triad Plc., a computer software development company that provides systems and consultants to the business community, where he was a director from 1987 to 1998, responsible for controlling the company financially.
From 1998 until the present day, Dr. Faulkes has focused on charitable activities, as the Founder and Sole Benefactor of the Dill Faulkes Educational Trust, a UK registered charity, where he is Chairman. He also sits on the Board of the Cambridge 800th Anniversary Campaign in the UK.
Job Titles:
- Independent Director
- Member of the Audit Committee
- Member of the Compensation Committee
- Member of the Nominations and Governance Team
- Audit
- British Physician
- Executive Medical Director of Western Sussex Hospitals NHS Trust
Dr. Barnes is a British physician with extensive experience both as a clinician and clinical manager within the UK National Health Service and related academic institutions. He was Consultant Neurologist at King's College Hospital London from 1995-2009 and Hon Senior Lecturer in Neurology at King's College London. He was Clinical Director for Neurology from 1995-98 and then Director of the King's Neurosciences Centre until 2008. During this period he oversaw the completion of the merger process that had resulted in the Centre's formation and then led its growth into the largest Regional Neurosciences Centre in the UK. He was the National lead for the NHS Action On Neurology service modernization programme from 2004-5 and between 2000 and 2009 was involved in a number of national and regional advisory groups for the Department of Health, NHS and pharmaceutical industry.
In 2009 Dr. Barnes became the Executive Medical Director of Western Sussex Hospitals NHS Trust, newly formed from the merger of two predecessor organizations. He led the medical aspects of merger, implemented the necessary changes in clinical culture to focus on quality improvement across the new organization and was part of the Board team that secured Foundation Trust status. He also had Board responsibility for Research and Development. In 2013 he moved to Medway NHS Foundation Trust and was employed as Executive Medical Director (including a year as Acting CEO) until his retirement from the NHS in 2016.
Dr. Barnes undertook his basic medical sciences training at King's College London winning a number of scholarships and prizes. He holds a BSc and PhD from the University of London. His doctoral research at King's studied the phenomenon of fatigue of neurohypophysial hormone secretion in vitro. He completed his clinical medical training as a Hobson Memorial Scholar at the Oxford University Clinical School graduating BMBCh in 1987. He undertook his postgraduate medical training in general medicine and neurology in Birmingham UK, Oxford and Nottingham and was a subspecialist in neuromuscular diseases. From 1991-1993 he was Neuromuscular Fellow in Oxford and EP Abraham Research Fellow and a member of the MRC Clinical and Biochemical Magnetic Resonance Unit, Oxford examining skeletal muscle bioenergetics in health and disease.
Dr. Barnes is a British physician with extensive experience both as a clinician and clinical manager within the UK National Health Service ("NHS") and related academic institutions. Dr. Barnes was also involved in a number of national and regional advisory groups for the Department of Health, NHS and pharmaceutical industry including being the national lead for the NHS Action On Neurology service modernization program. Dr. Barnes served as Executive Medical Director on a number of hospital and Foundation Trust Boards until his retirement from the NHS in 2016. Dr. Barnes holds a BSc and PhD from the University of London and his clinical medical degree (BM BCh) from the University of Oxford.
Job Titles:
- Member at the Carl R. Woese Institute for Genomic Biology
- Principal Investigator of the Comparative Oncology Research Laboratory
Dr. Timothy Fan serves as the principal investigator of the Comparative Oncology Research Laboratory housed in the Small Animal Clinic, Department of Veterinary Clinical Medicine at the University of Illinois and his research focuses on identifying molecular targets for improving treatment for canine and feline cancers.
Dr. Fan is a core member at the Carl R. Woese Institute for Genomic Biology in the Anticancer Discovery from Pets to People theme, and also serves as a Program Leader for the Cancer Center at Illinois that focuses on the inclusion of companion animals as sophisticated model systems to study cancer.
Uniquely, Dr. Fan's training as a scientist and veterinarian has allowed him the opportunity to rapidly investigate and translate novel treatment strategies in dogs and cats with spontaneously-arising cancers, and conduct meaningful comparative oncology research which is hoped to eventually aid in treating cancer in not only companion animals but also human beings.
Job Titles:
- Chief Executive Officer
- Chief Executive Officer of Volition Veterinary Diagnostic Development LLC
- Doctor of Veterinary Medicine
Tom Butera is a Doctor of Veterinary Medicine with more than 40 years of experience in equine and small animal health in private practice as well as extensive work in both business development and management of veterinary companies. Since 2016, he has been actively involved in business development roles with Mars Veterinary Health, leading divisions including Pet Partners, LLC, Banfield Pet Hospitals and Veterinary Centers of America (VCA). In his time with Mars, Dr. Butera has been instrumental in the acquisition of more than 60 small animal general practices and specialty/ER hospitals. Prior to joining Mars, Dr. Butera served as Co-Founder, Board Member and Chief Medical Officer of Pet Partners, LLC, an entity that owned and operated 68 small animal veterinary hospitals in 32 states in the U.S., employing approximately 450 veterinarians and 3,200 employees. Dr. Butera's veterinary business acumen was key to solidifying and growing Pet Partners' development pipeline, which ultimately positioned the company for overall sale to the Mars Veterinary Health family in April, 2016.
Dr. Butera earned his Doctor of Veterinary Medicine from the University of Missouri Veterinary School, going on to serve as an Assistant Professor at Tufts University Veterinary School heading the large animal anesthetic department for several years. Dr. Butera is an honorary member of the American Veterinary Medical Association and a licensed veterinarian in the Commonwealth of Massachusetts.
Job Titles:
- Independent Director
- Member of the Audit Committee
- Member of the Nominations and Governance Team
- Audit
- Member of Nominations and Governance Committee
- Member of the Institute of Chartered Accountants
Guy Archibald Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.
Mr. Innes has extensive experience in financing and managing technology companies, which he gained from serving as a non-executive director on the board of companies such as ProBio Inc. from 2000 to 2006, Magellan Copper & Gold Plc. from 2007 to 2010, and Carbon Mining Plc. from 2007 to 2010.
Prior to holding these directorships, Mr. Innes had a long career in banking and private equity, including advisory roles with Baring Brothers & Co. Limited in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers & acquisitions, but also IPOs and capital raising; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Quartz Capital Partners Limited from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions.
Mr. Innes was educated at the University of Bristol (BSc Geography), and is a Member of the Institute of Chartered Accountants in England and Wales.
Heather is a well-established veterinary medical oncologist specializing in canine models of human cancer. Her research over the past 15 years has focused on improving canine models of pediatric and adult cancers and translating these findings to the mutual benefit of both species. Her research focuses on stem cell biology, nucleosomics and cancer epigenetics as well as discovering new therapeutics for cancers in both canines and humans.
Job Titles:
- Chief Scientific Officer
- Scientist
Jake is the Chief Scientific Officer and one of the founding scientists of Volition. He is an experienced scientist with expertise in research and development in diagnostics both commercially and for the UK National Health Service and World Health Organization. Jake is the co-inventor and author of the patents surrounding Volition's Nucleosomics™ technology.
Jake received both his BSc in Biology and Chemistry and Ph.D. in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology from St Thomas' Hospital Medical School and his MBA from Imperial College Management School.
Jake is an experienced scientist with expertise in research and development and in the management of early stage biotechnical companies, including the manufacturing of biotechnology products and the establishment of manufacturing operations. Jake received his BSc in Biology and Chemistry, and his PhD in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology from St Thomas' Hospital Medical School, and his MBA from Imperial College Management School.
Job Titles:
- Chief Executive Officer of Singapore
Jasmine is the Chief Executive Officer of Singapore Volition having joined the company in 2017. She has a proven track record of developing strategic business alliances and has established great connections across Asia for Volition. As a thought leader in technology management and commercialization, Jasmine has worked with numerous health and regulatory bodies across Asia and has successfully commercialized technologies and expanded companies into the Asian markets.
Jasmine received a Bachelor of Engineering and a Doctor of Philosophy in Oceanography from the National University of Singapore.
Job Titles:
- Chief Medical Officer
- Jason Terrell MD / Chief Medical Officer
Jason is Volition's Chief Medical Officer. He has a strong grounding in both medicine and more specifically in diagnostics and product commercialization and has led both the clinical trial development program in the U.S. for Volition, in addition to supporting the launch of our first Veterinary product, the Nu.Q™ Vet Cancer Screening Test.
Since 2017 Jason also serves as Affiliate Faculty of the Department of Oncology at the Austin Dell Medical School, University of Texas.
He was educated at Hardin-Simmon University (Biochemistry) where he graduated Summa Cum Laude, also receiving the Holland Medal of Honor. He received his Doctor of Medicine from the University of Texas Medical School at Houston and affiliate MD Anderson Cancer Center.
Jason has been Affiliate Faculty in the Department of Oncology at the University of Texas at Austin Dell Medical School since 2017.
Job Titles:
- Independent Director
- Member of the Compensation Committee
- Member of the Nominations and Governance Team
- Compensation
- Member of Nominations and Governance Committee
Ms. Nguyen is an international HR professional with over 20 years-experience working with fast growing multinational technology companies covering Europe, Middle East & Africa, Latin America and Asia Pacific ("APAC") markets. Ms. Nguyen currently serves as VP of International HR at Binance, a blockchain company. Previously, Ms Nguyen was Head of HR for Google Asia Pacific Pte. Ltd where she led a 25-person HR team supporting over 15,000 employees across the APAC region. Ms. Nguyen holds a Bachelor of Science in Psychology (Hons) from the University of New South Wales, Sydney, Australia.
Job Titles:
- Chief Marketing and Communications Officer
Louise is the Chief Marketing and Communications Officer of Volition and has been a valued member of the team since joining in 2016. She brings more than 25 years of marketing, sales and leadership experience to her role at Volition. Formerly Louise worked in various roles at Reckitt Benckiser including some overseas posts in Paris and New York in addition to being Director and Owner of Aculd Ltd, a strategic marketing consultancy specializing in healthcare for five years.
Louise holds a Bachelor of Arts in Business Studies from Sheffield Hallam University.
Job Titles:
- Research & Development Director
Marielle is an epigeneticist with nearly 15 years research experience at the Institute of Genetics and Molecular and Cellular Biology (IGBMC), Strasbourg, the Laboratory ofCancer Epigenetics, Free University of Brussels and as the R&D director at Volition. She manages a team of four project managers and coordinates several external academic collaborations as well as outsourced commercial R&D and clinical programs.
Job Titles:
- Agent
- Independent Director
- Marketing Executive
- Member of the Compensation Committee
- Member of the Nominations and Governance Team
- Compensation
- Member of Nominations and Governance Committee
Mickie Henshall is a change agent and has specialized in transforming private equity-backed and public organizations into strong commercial companies through her talent in brand creation, portfolio development and marketing strategy. She is currently the Chief Marketing Officer at REALM IDx, the parent company of Ambry Genetics and Invicro, focused on ushering in the new field of integrated diagnostics.
For more than 20 years, Mickie has taken technology innovations to commercial success in life science, molecular diagnostic, clinical and hospital markets. Her deep understanding of science and regulatory compliance enabled her to lead Illumina to its first FDA 510(k), and secure FDA to green light Agena's strategy of a De Novo 510(k) for its oncology liquid biopsy monitoring test.
Mickie's leadership includes oversight of global markets, having led regional marketing teams in Europe, China and Australia.
Mickie is a seasoned marketing executive with over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries. Early on in her career, Ms. Henshall served as Associate Director of Diagnostics Marketing at Illumina, Inc. and has subsequently led global marketing operations at Biotix, Inc., Accriva Diagnostics, Inc. (acquired by Werfen Life), Agena Bioscience, Inc., and WGA (Genomic Life, Inc.). Mickie is currently Chief Marketing Officer at REALM IDx, Inc., a pioneering integrated diagnostics company.
Gael is the Chief Commercial Officer of Volition joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of products developed using the Nu.Q™ platform.
Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings.
Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
"I am delighted to work with the passionate team to drive commercialization of the product pipeline."
Mr. Gael Forterre has over 15 years of experience investing in and scaling fast growing companies. Mr. Forterre started his career as a hedge fund analyst in Paris and worked in a number of investment banking and trading roles over ten plus years, including launching Armori Capital Management LLC in 2014, for which he conducted a large number of investments on behalf of family offices/institutional investors and became active in supporting the growth of its portfolio companies. Most recently, from 2017 until joining Volition, he served as the Chief Executive Officer of Ucroo Incorporated, a fast-growing collaboration and communication technology company, which he led to a tripling in revenue growth two years in a row. Mr. Forterre continues to serve as a board member of Ucroo Incorporated and Article22.
Mr. Forterre holds a Master's degree in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.
Nick is the Group General Counsel of Volition and joined the company in November 2021. He has over 25 years' experience as a corporate and commercial lawyer, specializing in healthcare. Nick qualified with international law firm, Ashurst, and has since worked in-house for companies such as Ark Therapeutics PLC and Patheon, which is part of Thermo Fisher Scientific.
Nick joins Volition from Novacyt, the Anglo-French AIM listed diagnostic company, where he managed the legal function.
Job Titles:
- Independent Director
- Member of the Audit Committee
- Member of the Nominations and Governance Team
- Audit
- Chief Business Officer and Head of Corporate Strategy of Codiak BioSciences, Inc
Mr. Brudnick has held senior positions in the areas of Portfolio Strategy & Business Development and Corporate Development in a number of pharmaceutical companies and currently serves as Chief Business Officer at Prime Medicine, Inc, a biotechnology company committed to delivering a new class of differentiated, one-time, curative genetic therapies to address a wide spectrum of diseases.
Mr. Brudnick received a B.S. and M.S. in Management Science from the Massachusetts Institute of Technology.
Mr. Brudnick has held senior positions in the areas of Portfolio Strategy & Business Development and Corporate Development in a number of pharmaceutical companies and currently serves as Chief Business Officer and Head of Corporate Strategy of Codiak BioSciences, Inc., (NASDAQ GS: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a position he has held since June 2018. Mr. Brudnick received a B.S. and M.S. in Management Science from the Massachusetts Institute of Technology.
Rod is our Corporate Secretary and has been part of the Volition team right from its beginnings in 2011. He is an experienced legal and corporate secretary with over fifteen years' experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several mining companies in the United Kingdom.
Rod received a Bachelor of Laws degree from the University of Western Australia.
Job Titles:
- Head of Investor Relations
- Executive Vice President, Investor Relations & Chief Financial Officer of Volition America, Inc.
Scott is our Executive Vice President of Investor Relations and also serves as the Chief Financial Officer for Volition America Inc. He communicates regularly with existing and potential investors both one to one and at set piece conferences. Scott has over 20 years of experience in the U.S. capital markets and investor relations having served as Head of Investor Relations for four public companies, including Volition, and worked for several years as an investment banker.
He received his B.S. in Business Administration from Bryant University, both his MA and PhD degrees from Brown University and a Business Certificate from Columbia University in New York City.
Job Titles:
- General Manager, Belgian
- Healthcare Specialist
Sébastien is a healthcare specialist, having spent over 20 years in senior international consulting roles for companies such as IQVIA, Truven Health, and IBM Watson, focussing on market access. He also led a Belgian biotechnological startup, developing and commercializing an enzymatic cleaning…
Job Titles:
- Group Chief Financial Officer
Terig is the Group Chief Financial Officer of Volition having joined the company in February 2021. He is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience, including product commercialization, licensing and distributor management, gained through an international career spanning US, Europe and Asia.
Mr. Hughes is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning the United States, Europe and Asia and joins Volition from AUM Biosciences Pte. Ltd., a fast-growing biotechnology company focused on developing novel cancer drugs, where he acted as Chief Financial Officer since 2018. Prior to then, Mr. Hughes held a number of senior leadership positions at Elsevier, a division of RELX Group plc, a FTSE 100 company, including regional Managing Director and regional Finance Director for Elsevier Health Solutions. He has extensive experience in financial reporting, planning & analysis, and profit and loss management, as well as product commercialization, licensing and distributor management.
Terry has over 10 years of experience in Epigenetics including developing novel technologies and seeing them through to commercialization. She previously was the R&D Director at Active Motif and the Global leader for custom assays and services and Agena Bioscience. She received her PhD from UCLA and did Post-doctoral training at USC's Norris Cancer Center where she studied epigenetic regulation in cancer.